Results 31 to 40 of about 80,161 (286)

The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

Cardiovascular Diabetology, 2023
Background As indications for sodium-glucose co-transporter-2 inhibitors (SGLT2i) are expanding, a growing number of older adults have become candidates for treatment. We studied the safety profile of SGLT2i among older adults.
A. Goldman, B. Fishman, G. Twig, E. Raschi, T. Cukierman-Yaffe, Y. Moshkovits, A. Pomerantz, I. Ben-Zvi, R. Dankner, E. Maor   +9 more
semanticscholar   +1 more source

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus

Pharmaceutics, 2023
Type 2 diabetes mellitus is a major health problem worldwide with a steadily increasing prevalence reaching epidemic proportions. The major concern is the increased morbidity and mortality due to diabetic complications.
Melpomeni Peppa, Aspasia Manta, Ioanna Mavroeidi, Athina Asimakopoulou, Alexandros Syrigos, Constantinos Nastos, Emmanouil Pikoulis, Anastasios Kollias   +7 more
doaj   +1 more source

Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians

European Heart Journal, Supplement, 2023
The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce risks of clinical events in patients with heart failure (HF), with early and sustained benefits regardless of ejection fraction, diabetic status, and care setting.
L. Monzo, I. Ferrari, F. Cicogna, C. Tota, G. Cice, N. Girerd, L. Calò   +6 more
semanticscholar   +1 more source

Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

IJU Case Reports, 2019
Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects.
Keita Izumi, Yasumasa Iimura, Kiyoshi Hiruma, Tsuguhiro Touma, Tetsuro Tsukamoto   +4 more
doaj   +1 more source

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies

Frontiers in Pharmacology, 2023
Aims: This study aimed to investigate the association between the use of sodium-glucose transporter 2 inhibitors (SGLT-2i) and the risk of diabetic ketoacidosis (DKA), lower limb amputation (LLA), urinary tract infections (UTI), genital tract infections (
Chun Xing Li, T. Liu, Qian Zhang, Qing Xie, Xuhua Geng, C. Man, J. Li, X. Mao, Yue Qiao, Hua Liu   +9 more
semanticscholar   +1 more source

Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease

International Journal of Nephrology and Renovascular Disease, 2023
Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National ...
Isidto R, Danguilan R, Naidas O, Vilanueva R, Arakama MH, Paraiso LM   +5 more
doaj  

New possibilities of nephroprotection in patients with chronic heart failure in combination with chronic kidney disease and diabetes mellitus 2 or without it

Лечащий Врач, 2022
Impaired kidney function has a negative impact on the course of heart failure in both patients with and without diabetes mellitus. Therefore, the development and study of the effectiveness of methods for the treatment of chronic heart failure, especially
E. V. Kovalenko, L. I. Markova, O. L. Belaya   +2 more
doaj   +1 more source

The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis

Annals medicus, 2023
Background Despite the widespread use of classical cholesterol-lowering drugs to mitigate the adverse impacts of dyslipidaemia on atherosclerosis, many patients still face a substantial residual risk of developing atherosclerotic cardiovascular disease ...
P. Stachteas, P. Karakasis, D. Patoulias, F. Clemenza, N. Fragakis, Manfredi Rizzo   +5 more
semanticscholar   +1 more source

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome

Frontiers in Endocrinology, 2023
Cardio-renal-metabolic (CRM) syndrome, which involves type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and heart failure (HF), is a serious healthcare issue globally, with high morbidity and mortality.
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, T. Yajima   +3 more
semanticscholar   +1 more source

Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials

Diabetes, obesity and metabolism, 2023
To determine whether the magnitude of the cardiorenal benefits of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) varies with baseline kidney function.
E. Maddaloni, I. Cavallari, Y. La Porta, A. Appetecchia, L. D’Onofrio, F. Grigioni, R. Buzzetti, R. Holman   +7 more
semanticscholar   +1 more source